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INTRODUCTION
For patients with advanced stage squamous cell carcinoma of the
head and neck, chemoradiotherapy (CRT) is frequently used as
the primary treatment in order to achieve organ preservation and
to improve survival. However, most patients who are treated with
CRT for advanced head and neck cancer suffer from its side effects
such as dysphagia, mucositis, xerostomia and nausea. Severe oro-
pharyngeal mucositis leads to decreased oral food intake, result-
ing in interruption of CRT that may reduce its efficacy (1, 2).
Nasogastoric tube (NGT) is often placed as enteral nutritional
support for head and neck cancer patients with CRT-induced mu-
cositis. However, NGT is frequently associated with local irritation,
which might worsen mucositis, risk of aspiration pneumonia and
high frequency of occlusion. Recently, percutaneous endoscopic
gastrostomy (PEG) has been introduced for nutritional support for
patients with advanced head and neck cancer undergoing CRT
(3, 4). It was reported that in comparison with NGT, PEG was
equally effective in maintaining body weight with less rates of me-
chanical failure and aspiration pneumonia (5). Moreover, PEG has
additional advantages in term of mobility, cosmetics and quality of
life. Thus, PEG is now a safe and effective method of providing
enteral nutrition during CRT in patients with advanced head and
neck cancer.
In order to clarify if PEG placement improves the completion of
CRT and nutrition status in head and neck cancer patients, the
present study examined the efficacy of PEG on unplanned treat-
ment interruption and total serum protein levels in patients treated
with CRT for advanced head and neck cancer. For that purpose, we
recommended the placement of PEG in patients with inadequate
oral food intake of less than one third of their usual intake due to
severe CRT-induced mucositis. Then, we compared the rate of
treatment interruption and total serum protein concentration in
patients who accepted PEG placement with those who refused it.
PATIENTS AND METHODS
Patients and study design
We retrospectively reviewed hospital charts of 44 patients with
advanced head and neck cancer (38 males, 6 females, the average
age was 68.410.3 years old, 53-85 years old) who were treated
with CRT at the Department of Otolaryngology of Tokushima Uni-
versity Hospital. Tumor sites included : nasopharynx (n=7), oro-
pharynx (n=8), hypopharynx (n=13), larynx (n=10), oral cavity
(n=4), and metastatic cervical lymph nodes of unknown origin
(n=2). All patients were previously untreated and had locally ad-
vanced stage III or stage IV disease (Table 1). The radiation dose
was approximately 70 Gy, and chemotherapy usually consisted of
cisplatin and 5-fluorouracil. We performed concurrent CRT, except
alternative CRT for nasopharyngeal cancer. This study was ap-
proved by the Committee for Medical Ethics of Tokushima Uni-
versity Hospital.
Treatment and placement of PEG
Indications criteria for PEG placement were as follows : CRT-
induced mucositis of grade 3 or worse on common terminology
criteria for adverse events (CTCAE Version 4.0) and inadequate
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oral intake of less than one third of usual intake during CRT. This
is because in patients with CRT-induced mucositis of grade 3, after
their nutritional intake becomes less than one third of usual intake,
protein catabolism is enhanced resulting in delayed healing of mu-
cositis and exacerbation of patient’s malnutrition (6-9). Thirty three
patients who met the criteria for PEG placement during CRT were
recommended to be managed by this method for nutritional sup-
port. Among them, 13 patients accepted PEG placement (the com-
pliant group), which was performed by surgeons at the Department
of Surgery of Tokushima University Hospital. On the other hand,
20 patients refused both PEG and NGT placements (the non-com-
pliant group), while the remaining 11 patients did not meet the cri-
teria for PEG placement (non- indication group).
PEG was placed using the Pull method, as described by Ponsky
et al. (10). No complications were associated with PEG tube place-
ment such as local infections, tube blockage, migration or dislodge-
ment.
CRT-induced non-hematologic toxicity of grade 3 or worse
(other than mucositis) and CRT-induced hematologic toxicity of
grade 4 led to the interruption of CRT. But, in patients with only
CRT-induced mucositis of grade 3 or worse without hematologic
toxicity of grade 4, CRT was interrupted when patient had diffi-
culty eating.
Assessment of total serum protein levels
Total serum protein (TP) levels were measured before and after
CRT in all patients and taken as an index of nutritional status.
Statistical analysis
Fisher’s exact probability test, Student’s t - test and ANOVA with
Kruskal -Wallis post hoc test were used for statistical analysis, and
P0.05 was considered significant.
RESULTS
Efficacy of PEG on treatment interruption of chemoradiotherapy
All 44 patients who were treated with CRT for advanced head
and neck cancer suffered from CRT-induced mucositis of grade 3
or worse and 33 of them developed inadequate oral intake of less
than one third of their usual intake. Because they met our criteria
for PEG placement during CRT, we recommended them for this
nutritional support method. Among them, 13 patients accepted
PEG placement (the compliant group) and then completed CRT.
However, 20 patients refused both PEG and NGT placements (the
non-compliant group). Thereafter, unplanned interruptions of CRT
were required in 10 patients who had difficulty eating (Fig. 1). The
interruption rate was 50% in non-compliant group, a significant
increase compared with that of the compliant group (Table 2). In
the non-compliant group, CRT interruption periods were 6 to 35
days (10.58.8 days) and reached 80% in most of them, while CRT
was interrupted at a radiation dose around 30-40 Gy (Fig. 2). The
other 10 non-compliant patients could complete CRT without inter-
ruption. The remaining 11 patients of the non- indication group
also completed CRT without interruption.
Efficacy of PEG on nutritional status
Serum TP levels were significantly decreased after CRT in each
group (Fig. 3). The decrease rate of serum TP in the compliant
group was 6.49.0% (meanSD) ; 6.4%7.6 in the non-compliant
group ; 13.18.7% in patients who completed CRT without inter-
ruption, and 8.37.4% in those of the non- indication group. There
were not significant differences among groups.
Adverse events except mucositis during chemoradiotherapy
In the compliant and non-compliant groups, 4 patients suffered
Table 1 Patient characteristics
Tumor site n
Mean age
(years)
Male Female StageStage
Nasopharynx 7 68.914.0 6 1 4 3
Oropharynx 8 63.19.9 6 2 2 6
Hypopharynx 13 69.311.9 12 1 2 11
Larynx 10 67.67.6 10 0 5 5
Oral cavity 4 74.86.2 4 0 1 3
unknown origin 2 77.59.2 0 2
Total 44 38 6
Data show as either n, or meanstandard deviation.
Fig. 1 : Patients flowchart. PEG : percutaneous endoscopic gastrostomy,
CRT : chemoradiotherapy.
Table 2 Interruption rate of chemoradiotherapy in patients with ad-
vanced head and neck cancer
PEG placement Interruption rate of CRT
Compliant group 0% (0/13)
Non-compliant group 50%* (10/20)
Non- indication group 0% (0/11)
*p0.01 vs. compliant and non-compliant patients group.
PEG : percutaneous endoscopic gastrostomy, CRT : chemoradiotherapy.
Fig. 2 : Doses of radiation at interruption of CRT in non-compliant pa-
tients with advanced head and neck cancer. PEG : percutaneous endo-
scopic gastrostomy, CRT : chemoradiotherapy.
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from grade 3 leukopenia in each group, while 1 patient suffered
from both grade 4 leukopenia of and grade 3 dermatitis at the in-
terruption of CRT. There was no significant difference in the fre-
quency of grade 3 leukopenia between the groups.
DISCUSSION
Most patients with advanced head and neck cancer have some
degree of malnutrition, which is deteriorated by toxic side-effects
during CRT. Although NGT is useful for short - term nutritional sup-
port, PEG is indicated for long-term nutritional support when oral
intake is inadequate. In the present study, of 44 patients who were
treated with CRT for advanced head and neck cancer, 33 met the
criteria for PEG placement. Among them, 13 patients accepted the
placement and subsequently completed their CRT. However, among
the 20 patients who refused both PEG and NGT placements, un-
planned interruptions of CRT were required in 10 of them. Their
interruption period ranged from 1 week to 4 weeks. Patel, et al. re-
ported that advanced head and neck cancer patients who required
break of radiation for more than 2 weeks were significantly more
likely to have residual tumor in the neck after CRT (2). McCloskey,
et al. also reported that CRT interruption of more than a week con-
stitutes a significant higher risk of loco-regional recurrence of tu-
mor (1). Therefore, it is suggested that PEG placement is useful
for preventing unplanned interruption of CRT in patients with ad-
vanced head and neck cancer, resulting in improvement of their
residual and recurrent rates of tumor. Prospective controlled stud-
ies are necessary to clarify whether PEG placement improves the
prognosis of advanced head and neck cancer.
In the present study, among 10 patients who refused both PEG
and NGT placements, unplanned interruptions of CRT were re-
quired at a radiation dose around 30-40 Gy in 8 patients. The in-
dication of therapeutic PEG placement is still controversial, because
no single marker can be used to identify malnutrition (3, 4). There-
fore, after severe mucositis and inadequate oral intake have de-
veloped, therapeutic PEG placement should be considered before
the dose of 30 Gy in patients with advanced head and neck cancer
undergoing CRT.
The same as for patients in whom PEG placement was indicated,
serum TP levels were significantly decreased after CRT in those
who did not undergo the procedure. This finding suggests that
malnutrition further developed even in patients with mild/moderate
CRT-induced mucositis during CRT. Moreover, it is suggested
that therapeutic PEG placement did not prevent malnutrition, be-
cause TP levels were decreased even in patients who accepted it.
All patients who accepted PEG placement completed CRT with-
out interruption regardless of their significant decrease of serum
TP levels after CRT. It may be suggested that enteral feeding by
PEG placement improve nutritional status that can’t be estimated
by only serum TP levels. Since malnutrition is a strong independ-
ent predictor of survival in patients with advanced head and neck
cancer (11), prophylactic PEG is recommended in all patients with
advanced head and neck cancer before CRT.
Recently, a randomized controlled trial showed evidence for pro-
phylactic PEG placement in the prevention of malnutrition and
improved quality of life in patients with advanced head and neck
cancer (12). Moreover, Raykher reported that PEG feeding allowed
CRT to continue without interruption in 93% of patients with head
and neck cancer (13). However, Lee et al. reported that prophylac-
tic PEG had no effect in the rate of treatment interruption in patients
undergoing intensive radiation therapy for head and neck cancer
(14). In the present study, based on our indication criteria for of
PEG placement including CRT-induced mucositis of grade 3 or
worse and inadequate oral intake of less than one third of the usual
intake, 11 patients (25%) did not meet our indication criteria, but
completed CRT uninterrupted without PEG. Therefore, it is sug-
gested that prophylactic PEG placement is not needed before CRT
in all head and neck cancer patients and therapeutic PEG placement
is preferred in response to inadequate oral intake during CRT.
Further study is necessary to examine whether prophylactic or
therapeutic PEG placement is warranted in the treatment of ad-
vanced head and neck cancer by CRT (15).
The pull method of PEG placement in patients with head and
neck cancer is widely applied, because it is easy to perform and
can be accomplished without general anesthesia, though there is
a possibility of exit site metastasis due to the pull method. However,
the risk is accepted, because it is very low (1%) (16).
There is also the possibility that PEG placement during CRT in-
creases the risk of surgical site infection and bleeding of CRT-
induced mucositis. To reduce the risk, PEG was placed more than
a week before or after chemotherapy in the study. Accordingly, no
surgical complications developed.
In conclusion, in patients undergoing CRT for advanced head
and neck cancer, the efficacy of PEG on its unplanned interruption
was examined. Therapeutic PEG placement was useful in prevent-
ing unplanned interruption of CRT. After severe mucositis and in-
adequate oral intake have developed during CRT, PEG placement
should be considered before the dose of 30 Gy.
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